On 27 September 2024, Sanofi and Regeneron announced that Dupixent® (dupilumab) has been approved in the US as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. On the same date, the companies announced that China’s National Medical Products Administration (NMPA) has approved Dupixent® for the same indication.
This follows the UK approval of Dupixent® as an add-on maintenance treatment for COPD earlier this month.
In July 2024, Dupixent® received European approval as an add-on maintenance treatment for adults with uncontrolled COPD, the first approval of Dupixent® for COPD anywhere in the world. In the same month, Sanofi reported that Q2 2024 Dupixent® sales grew by 29.2% to over €3.3B.